In this free webinar, attendees will get a 360-degree view of the progress being made in the NK cell space including advances in technology, emergence of new business strategies, maturation of new manufacturing paradigms, and implications associated with the latest clinical findings. The featured speakers will discuss the clinical promise and challenges associated with the widespread adoption of NK cell-based therapies.
Natural killer (NK) cells have moved front and center as one of the most exciting therapeutic technologies in clinical development. They are considered by many experts to be a critical cell type in the fight against solid tumors.
The goal of this webinar is to provide a complete view of the progress being made in NK cell therapies alongside the promise and challenges they present as they move into the clinic.
Technology aspects: What is the lay of the land in the NK space? What improved technologies are emerging and being incorporated into the next generation of NK cell therapies? How are these new technologies enabling commercial readiness and creating meaningful opportunities to elevate the standard of care in solid tumor indications?
Manufacturing aspects: How have these novel therapeutic modalities enabled the emergence of new and scalable manufacturing platforms? What are some of the unique challenges and opportunities surrounding the manufacture of NK cells? What have we learned from the early adoption of T cell-based therapies, and how can we apply these lessons to mitigate challenges in production and ensure the delivery of life-saving treatments at commercial scale?
Clinical aspects: Why NK cells? How do they work? What is unique and compelling about their mechanism of action and why could this be advantageous in the fight against solid tumors? What is the latest thinking regarding combination therapies to drive meaningful improvements in clinical outcomes beyond the current standard of care? How might dosing strategies evolve to improve clinical outcomes and promote persistence?
Join the featured speakers to discuss NK cells, one of the fastest growing segments of the cell therapy industry.
Join Christina Coughlin, CEO, CytoImmune Therapeutics; Evren Alici, Associate Professor, Cell and Gene Therapy Group, Department of Medicine, Karolinska Institute; Volker Huppert, Chief Development Officer, Glycostem; Martin A. Giedlin, PhD, VP, Head Tech Ops, Senti Bio; Ezequiel Zylberberg, Vice President, Product Development and Planning, Akron Bio; and Robert Margolin, Vice President of Commercial, BioProducts Business, Akron Bio, for the live webinar on Thursday, August 18, 2022, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Natural Killer Cells: Progress and Promise.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food, and medical device communities. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/